March 27, 2017 7:40 PM ET

Pharmaceuticals

Company Overview of Laboratorios SALVAT, S.A.

Company Overview

Laboratorios SALVAT, S.A. manufactures pharmaceutical products for personal healthcare, digestive/metabolism, urology, ENT/ophthalmology, dermatology, and malaria. The company also engages in research projects in molecular diagnosis, regenerative medicine, and new forms of drug delivery. It offers its products in solid, semi-solid, and liquid pharmaceutical forms; specializes in blow-fill-seal contract manufacturing of small fill volume pharmaceutical unit dose sterile liquids, which include ear drops, eye drops, and other products. It markets its products through local licensees and distributors in Europe, America, Asia, Africa, and the Middle East. Laboratorios SALVAT, S.A. was founded in ...

C\ Gall, 30-36

Barcelona,  08950

Spain

Founded in 1955

Phone:

34 933 94 64 00

Fax:

34 934 73 22 92

Key Executives for Laboratorios SALVAT, S.A.

General Manager
Chief Operating Officer
Managing Director
Medical Research Director
Compensation as of Fiscal Year 2016.

Laboratorios SALVAT, S.A. Key Developments

iCo Therapeutics Announces Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset

iCo Therapeutics announced a World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for a Novel Glaucoma Asset. Glaucoma candidate a novel and potentially first in class asset. Salvat to market glaucoma drug in EU with iCo receiving royalties. Exclusive option to acquire asset outright over multiple development stage milestones aggregate payments either $4.25 million or $4.5 million, based on option exercise timing. iCo obtains a worldwide exclusive option to glaucoma asset for a maximum of nine months iCo diligence activities during option period to focus on commercialization of asset. During option period minimal impact on corporate runway. SALVAT will continue to pay intellectual property costs during option period to date 29 patents have been issued.

Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) Otic Solution

Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC jointly announce the launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution, the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials. OTOVEL® is owned by SALVAT, and Arbor will be the exclusive distributor of the product in the U.S. OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (aged 6 months and older) due to S. aureus, S. pneumoniae, H. influenzae, M. catarrhalis, and P. aeruginosa. Two phase 3 multicenter, randomized, double-blind, active-controlled, parallel group trials were conducted to assess the efficacy and safety of OTOVEL® compared to ciprofloxacin otic solution and to fluocinolone acetonide otic solution.

Laboratorios Salvat Signs Distribution Agreement with Lee's Pharmaceutical (Hong Kong) and Taiwan

Laboratorios Salvat (Spain) and Lee's Pharmaceutical (Hong Kong) have signed a licence and supply agreement for the marketing and distribution of Duoxal (ciprofloxacin + fluocinolone acetonide) ear drops in mainland China, Hong Kong, Macau, and Taiwan, with an option to add Thailand, the companies said in a statement. Duoxal is indicated for the treatment of acute otitis media in patients with tympanostomy tubes, and acute otitis externa (swimmer's ear) in adults and children older than six months of age.

Similar Private Companies By Industry

Company Name Region
Ability Pharmaceuticals, S.L. Europe
Activery Biotech SL Europe
Aelix Therapeutics SL Europe
AlbaJuna Therapeutics SL Europe
Alcaliber S.A. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Laboratorios SALVAT, S.A., please visit www.salvatbiotech.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.